Encinitas, California--(Newsfile Corp. - July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer, will present at the Jones Trading Healthcare Seaside Summit on Monday, July 15 at 6:15 pm Eastern Time (3:15 PM Pacific Time).
The presentation will be available to investors live and on-demand from this registration link (https://wsw.com/webcast/jones/kprx/1853019). The on-demand replay will be available for 90 days on Kiora's Investor Relations homepage (ir.kiorapharma.com).
Following the event, Kiora invites shareholders to submit questions related to the above presentation on any topics including our clinical development plans, the science behind our investigational therapies and Kiora's financials. Verified retail and institutional shareholders will be able to submit and upvote questions you would like answered through a dedicated Q&A portal. The portal will open for questions July 16th at 9:00 am EDT and close July 19 at 11:00 am EDT. To submit questions, please visit https://app.saytechnologies.com/kprx-2024-jones/.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Contacts:
Investors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
This email address is being protected from spambots. You need JavaScript enabled to view it.
Crowe PR
| Last Trade: | US$2.31 |
| Daily Change: | -0.24 -9.41 |
| Daily Volume: | 79,019 |
| Market Cap: | US$7.920M |
August 07, 2025 July 22, 2025 June 03, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
